biote Corp.

Name: biote Corp. standardized financial statements, quarterly
Creator: Listed

BTMDNasdaqCIK 1819253HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$44.2m, Q2 FY2026

Operating income−$3.5m, Q2 FY2026

Net income−$6.6m, Q2 FY2026

biote Corp., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	45.6	45.7	46.8	49.2	51.4	49.8	49.0	48.9	48.0	46.4	44.9	44.2
Selling, general and administrative	$m	23.8	26.2	22.9	27.6	23.9	33.0	26.7	24.2	26.2	24.7	27.8	32.4
Operating income	$m	7.6	5.5	10.4	6.2	12.2	2.8	9.7	10.8	8.3	6.8	3.2	(3.5)
Income tax	$m	3.9	(2.7)	2.4	0.1	3.2	(4.7)	1.6	2.2	(0.8)	3.0	0.7	0.3
Net income	$m	7.5	7.7	(4.2)	(7.1)	10.7	3.7	13.7	3.2	8.2	2.0	2.3	(6.6)
Diluted EPS	$ per share	0.24	not reported	(0.12)	(0.21)	0.33	not reported	0.37	0.10	0.22	not reported	0.06	(0.23)
Basic EPS	$ per share	0.25	not reported	(0.12)	(0.21)	0.34	not reported	0.44	0.10	0.26	not reported	0.07	(0.23)

Balance sheet

Cash and equivalents$11.2m, Q2 FY2026

Long-term debt$118.4m, Q2 FY2026

Shareholders' equity−$65.8m, Q2 FY2026

biote Corp., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	65.6	89.0	78.8	26.4	38.2	39.3	41.7	19.6	28.0	24.1	5.3	11.2
Current assets	$m	118	122	114	61.8	70.0	68.1	68.7	49.5	57.1	54.7	36.4	43.0
Total assets	$m	150	155	160	92.9	101	122	123	105	111	108	89.0	102
Current liabilities	$m	25.1	22.2	24.1	46.3	46.5	51.5	48.5	50.5	56.3	45.0	28.2	30.1
Total liabilities	$m	201	192	205	235	228	225	208	184	177	158	137	160
Long-term debt	$m	108	107	105	104	103	101	99.8	98.5	97.1	95.8	94.4	118
Current portion of debt	$m	6.3	6.3	6.3	6.3	6.3	6.3	6.3	6.3	6.3	6.3	6.3	3.1
Shareholders' equity	$m	(40.5)	(29.4)	(36.0)	(143)	(130)	(106)	(90.0)	(85.1)	(72.8)	(58.5)	(56.1)	(65.8)

Cash flow

Operating cash flow−$1.2m, Q2 FY2026

Capital expenditure$2.6m, Q2 FY2026

Share repurchases$4.8m, Q2 FY2026

biote Corp., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	0.2	7.0	7.4	9.9	15.6	12.4	6.5	7.1	14.1	7.6	3.9	(1.2)
Capital expenditure	$m	0.5	(0.2)	0.7	2.5	1.6	1.7	1.6	1.8	0.5	1.1	0.4	2.6
Dividends paid	$m	1.0	1.1	0.1	4.1	0.5	0.1	0.7	0.9	0.0	0.1	0.4	0.6
Share repurchases	$m	not reported	not reported	4.1	1.5	0.0	0.0	not reported	not reported	not reported	0.0	1.1	4.8

Diluted shares (weighted)28.63m, Q2 FY2026

biote Corp., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	7.6	17.6	20.7	31.0	34.6	33.1	32.3	37.0	31.7	36.7	36.0	28.6

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.

biote Corp.

Income statement

Balance sheet

Cash flow

Shares